Response to L-DOPA in multiple system atrophy

E. A. Parati, V. Fetoni, G. C. Geminiani, P. Soliveri, P. Giovannini, D. Testa, S. Genitrini, T. Caraceni, F. Girotti

Research output: Contribution to journalArticle

Abstract

A poor response to L-DOPA in addition to parkinsonian, cerebellar, and autonomic signs is commonly regarded as indicative of clinical multiple system atrophy (MSA). We compared the motor response to a single oral administration of 250 mg L-DOPA/25 mg carbidopa in eight MSA patients and eight Parkinson's disease (PD) patients with the 'on-off' phenomenon, evaluating L-DOPA peripheral pharmacokinetics. Motor response was consistently good in all PD patients, but only four MSA patients had a (moderate) response. Pharmacokinetic parameters did not differ between the groups. The varying extent of putaminal damage could be responsible for the differing motor response to L-DOPA in MSA patients.

Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalClinical Neuropharmacology
Volume16
Issue number2
Publication statusPublished - 1993

Fingerprint

Multiple System Atrophy
Parkinson Disease
Pharmacokinetics
Carbidopa
Oral Administration

Keywords

  • L-DOPA
  • Multiple system atrophy
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Parati, E. A., Fetoni, V., Geminiani, G. C., Soliveri, P., Giovannini, P., Testa, D., ... Girotti, F. (1993). Response to L-DOPA in multiple system atrophy. Clinical Neuropharmacology, 16(2), 139-144.

Response to L-DOPA in multiple system atrophy. / Parati, E. A.; Fetoni, V.; Geminiani, G. C.; Soliveri, P.; Giovannini, P.; Testa, D.; Genitrini, S.; Caraceni, T.; Girotti, F.

In: Clinical Neuropharmacology, Vol. 16, No. 2, 1993, p. 139-144.

Research output: Contribution to journalArticle

Parati, EA, Fetoni, V, Geminiani, GC, Soliveri, P, Giovannini, P, Testa, D, Genitrini, S, Caraceni, T & Girotti, F 1993, 'Response to L-DOPA in multiple system atrophy', Clinical Neuropharmacology, vol. 16, no. 2, pp. 139-144.
Parati EA, Fetoni V, Geminiani GC, Soliveri P, Giovannini P, Testa D et al. Response to L-DOPA in multiple system atrophy. Clinical Neuropharmacology. 1993;16(2):139-144.
Parati, E. A. ; Fetoni, V. ; Geminiani, G. C. ; Soliveri, P. ; Giovannini, P. ; Testa, D. ; Genitrini, S. ; Caraceni, T. ; Girotti, F. / Response to L-DOPA in multiple system atrophy. In: Clinical Neuropharmacology. 1993 ; Vol. 16, No. 2. pp. 139-144.
@article{577c04256b1e412db1697056463ee4da,
title = "Response to L-DOPA in multiple system atrophy",
abstract = "A poor response to L-DOPA in addition to parkinsonian, cerebellar, and autonomic signs is commonly regarded as indicative of clinical multiple system atrophy (MSA). We compared the motor response to a single oral administration of 250 mg L-DOPA/25 mg carbidopa in eight MSA patients and eight Parkinson's disease (PD) patients with the 'on-off' phenomenon, evaluating L-DOPA peripheral pharmacokinetics. Motor response was consistently good in all PD patients, but only four MSA patients had a (moderate) response. Pharmacokinetic parameters did not differ between the groups. The varying extent of putaminal damage could be responsible for the differing motor response to L-DOPA in MSA patients.",
keywords = "L-DOPA, Multiple system atrophy, Parkinson's disease",
author = "Parati, {E. A.} and V. Fetoni and Geminiani, {G. C.} and P. Soliveri and P. Giovannini and D. Testa and S. Genitrini and T. Caraceni and F. Girotti",
year = "1993",
language = "English",
volume = "16",
pages = "139--144",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Response to L-DOPA in multiple system atrophy

AU - Parati, E. A.

AU - Fetoni, V.

AU - Geminiani, G. C.

AU - Soliveri, P.

AU - Giovannini, P.

AU - Testa, D.

AU - Genitrini, S.

AU - Caraceni, T.

AU - Girotti, F.

PY - 1993

Y1 - 1993

N2 - A poor response to L-DOPA in addition to parkinsonian, cerebellar, and autonomic signs is commonly regarded as indicative of clinical multiple system atrophy (MSA). We compared the motor response to a single oral administration of 250 mg L-DOPA/25 mg carbidopa in eight MSA patients and eight Parkinson's disease (PD) patients with the 'on-off' phenomenon, evaluating L-DOPA peripheral pharmacokinetics. Motor response was consistently good in all PD patients, but only four MSA patients had a (moderate) response. Pharmacokinetic parameters did not differ between the groups. The varying extent of putaminal damage could be responsible for the differing motor response to L-DOPA in MSA patients.

AB - A poor response to L-DOPA in addition to parkinsonian, cerebellar, and autonomic signs is commonly regarded as indicative of clinical multiple system atrophy (MSA). We compared the motor response to a single oral administration of 250 mg L-DOPA/25 mg carbidopa in eight MSA patients and eight Parkinson's disease (PD) patients with the 'on-off' phenomenon, evaluating L-DOPA peripheral pharmacokinetics. Motor response was consistently good in all PD patients, but only four MSA patients had a (moderate) response. Pharmacokinetic parameters did not differ between the groups. The varying extent of putaminal damage could be responsible for the differing motor response to L-DOPA in MSA patients.

KW - L-DOPA

KW - Multiple system atrophy

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0027506118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027506118&partnerID=8YFLogxK

M3 - Article

C2 - 8477409

AN - SCOPUS:0027506118

VL - 16

SP - 139

EP - 144

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 2

ER -